{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:15Z","timestamp":1791903315474,"version":"4.3.4"},"reference-count":73,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Comutations of addition of sex combs-like 1 (asxl1) and isocitrate dehydrogenases 2 (IDH2) are associated with aggressive acute myeloid leukemia (AML), yet the underlying mechanisms have remained poorly understood. We generated a zebrafish model combining an asxl1 mutation and an IDH2R172K mutation that recapitulates the clinicopathological and molecular features of high-risk AML with differentiation blockade and reduced animal survival. The double mutants exhibited promoter hypermethylation, downregulation of tet2 expression, and global changes in methylation profiles. Genes pertaining to MAPK and activator protein-1 (AP-1) pathways were upregulated, which was associated with reduced NAD phosphate oxidase expression and an increase in reactive oxygen species (ROS). Single-cell RNA sequencing confirmed differentiation arrest in hematopoietic stem and progenitor cells, with activation of MAPK and AP-1 signaling. The double mutants showed resistance to the IDH2 inhibitor but were sensitive to ROS or DNA methylation targeting. In silico analysis of gene expression in human AML carrying comutation of ASXL1\/IDH2 also showed activation of the MAPK and AP-1 pathways. Our findings underscore an epigenetic-metabolic signaling circuit driving leukemogenesis and reveal novel therapeutic strategies for this AML subtype.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026019586","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T23:22:03Z","timestamp":1784848923000},"page":"6610-6625","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["Comutation of\n                    <i>asxl1<\/i>\n                    and\n                    <i>IDH2<\/i>\n                    R172K enhances leukemogenesis and correlates with epigenetic activation of MAPK and AP-1 in zebrafish"],"prefix":"10.1182","volume":"10","author":[{"given":"Eleanor Fangfang","family":"He","sequence":"first","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao","family":"Ruan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingge","family":"Tu","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Miao","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Mun","family":"Liew","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lichuan","family":"Zheng","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-0561","authenticated-orcid":false,"given":"Chun-fung","family":"Sin","sequence":"additional","affiliation":[{"name":"2Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2770-0990","authenticated-orcid":false,"given":"Xudong","family":"Liu","sequence":"additional","affiliation":[{"name":"3Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Shao","sequence":"additional","affiliation":[{"name":"3Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth Kin Leung","family":"Kwan","sequence":"additional","affiliation":[{"name":"2Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie Kar-Fai","family":"Chan","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7325-1250","authenticated-orcid":false,"given":"Jeffrey Wan Hei","family":"Hui","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4355-4293","authenticated-orcid":false,"given":"Annie Wan Yu","family":"Ho","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze Pui","family":"Tsui","sequence":"additional","affiliation":[{"name":"2Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runsheng","family":"Li","sequence":"additional","affiliation":[{"name":"3Department of Infectious Diseases and Public Health, City University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen Chak-Lui","family":"Wong","sequence":"additional","affiliation":[{"name":"2Department of Pathology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvin Chun Hang","family":"Ma","sequence":"additional","affiliation":[{"name":"4ZeBlast Technology Limited, Hong Kong Science Park, Hong Kong SAR, China"},{"name":"5Department of Health Technology and Informatics, The Hong Kong Polytechnic University, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9402-3523","authenticated-orcid":false,"given":"Yiyue","family":"Zhang","sequence":"additional","affiliation":[{"name":"6Division of Cell, Developmental, and Integrative Biology, School of Medicine, South China University of Technology, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3636-7133","authenticated-orcid":false,"given":"Wenqing","family":"Zhang","sequence":"additional","affiliation":[{"name":"6Division of Cell, Developmental, and Integrative Biology, School of Medicine, South China University of Technology, Guangzhou, China"},{"name":"7Department of Hematology, Guangzhou First People\u2019s Hospital, School of Medicine, South China University of Technology, Guangzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anskar Yu Hung","family":"Leung","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"4ZeBlast Technology Limited, Hong Kong Science Park, Hong Kong SAR, China"},{"name":"8Centre for Oncology and Immunology, Hong Kong Science Park, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3051-1720","authenticated-orcid":false,"given":"Xuan","family":"Sun","sequence":"additional","affiliation":[{"name":"1Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China"},{"name":"4ZeBlast Technology Limited, Hong Kong Science Park, Hong Kong SAR, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"issue":"1","key":"2026101310425877500_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3343\/alm.2021.41.1.25","article-title":"Application of next generation sequencing in laboratory medicine","volume":"41","author":"Zhong","year":"2021","journal-title":"Ann Lab Med"},{"issue":"1","key":"2026101310425877500_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40291-019-00443-9","article-title":"Clinical utility of next-generation sequencing in acute myeloid leukemia","volume":"24","author":"Yang","year":"2020","journal-title":"Mol Diagn Ther"},{"issue":"13","key":"2026101310425877500_bib3","doi-asserted-by":"crossref","first-page":"3280","DOI":"10.3390\/cancers15133280","article-title":"Impact of next-generation sequencing in diagnosis, prognosis and therapeutic management of acute myeloid leukemia\/myelodysplastic neoplasms","volume":"15","author":"Madaci","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2026101310425877500_bib4","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1182\/blood-2018-04-848028","article-title":"Next-generation sequencing-based posttransplant monitoring of acute myeloid leukemia identifies patients at high risk of relapse","volume":"132","author":"Kim","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2026101310425877500_bib5","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1182\/bloodadvances.2023011757","article-title":"Prognostic risk signature in patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax","volume":"8","author":"Bataller","year":"2024","journal-title":"Blood Adv"},{"issue":"49","key":"2026101310425877500_bib6","doi-asserted-by":"crossref","first-page":"19611","DOI":"10.1073\/pnas.1117773108","article-title":"Hypoxia promotes isocitrate dehydrogenase-dependent carboxylation of \u03b1-ketoglutarate to citrate to support cell growth and viability","volume":"108","author":"Wise","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026101310425877500_bib7","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1038\/s41467-024-47536-6","article-title":"Wild-type IDH2 is a therapeutic target for triple-negative breast cancer","volume":"15","author":"Li","year":"2024","journal-title":"Nat Commun"},{"issue":"16","key":"2026101310425877500_bib8","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/s41388-023-02611-y","article-title":"Transgenic IDH2R172K and IDH2R140Q zebrafish models recapitulated features of human acute myeloid leukemia","volume":"42","author":"Wang","year":"2023","journal-title":"Oncogene"},{"issue":"10","key":"2026101310425877500_bib9","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41408-020-00373-4","article-title":"Redefining prognostication of de novo cytogenetically normal acute myeloid leukemia in young adults","volume":"10","author":"Tsui","year":"2020","journal-title":"Blood Cancer J"},{"issue":"7274","key":"2026101310425877500_bib10","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"issue":"3","key":"2026101310425877500_bib11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ccr.2010.01.020","article-title":"The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate","volume":"17","author":"Ward","year":"2010","journal-title":"Cancer Cell"},{"issue":"5","key":"2026101310425877500_bib12","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/embor.2011.43","article-title":"The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases","volume":"12","author":"Chowdhury","year":"2011","journal-title":"EMBO Rep"},{"issue":"1","key":"2026101310425877500_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ccr.2010.12.014","article-title":"Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of \u03b1-ketoglutarate-dependent dioxygenases","volume":"19","author":"Xu","year":"2011","journal-title":"Cancer Cell"},{"issue":"5","key":"2026101310425877500_bib14","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1038\/s41375-018-0026-z","article-title":"IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies","volume":"32","author":"Meggendorfer","year":"2018","journal-title":"Leukemia"},{"issue":"S3","key":"2026101310425877500_bib15","doi-asserted-by":"crossref","first-page":"e09323c5","DOI":"10.1097\/01.HS9.0000968724.09323.c5","article-title":"Acute myeloid leukemia (AML) with IDH1 and IDH2 mutations can be effectively risk stratified based on the presence adverse risk genomic features [abstract]","volume":"7","author":"Bhide","year":"2023","journal-title":"Hemasphere"},{"issue":"5","key":"2026101310425877500_bib16","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2021004934","article-title":"Differential impact of IDH1\/2 mutational subclasses on outcome in adult AML: results from a large multicenter study","volume":"6","author":"Middeke","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2026101310425877500_bib17","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13045-022-01336-x","article-title":"ASXL1\/2 mutations and myeloid malignancies","volume":"15","author":"Medina","year":"2022","journal-title":"J Hematol Oncol"},{"issue":"2","key":"2026101310425877500_bib18","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/bjc.2013.281","article-title":"Functional and cancer genomics of ASXL family members","volume":"109","author":"Katoh","year":"2013","journal-title":"Br J Cancer"},{"issue":"2","key":"2026101310425877500_bib19","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/leu.2009.218","article-title":"Mutual exclusion of ASXL1 and NPM1 mutations in a series of acute myeloid leukemias","volume":"24","author":"Carbuccia","year":"2010","journal-title":"Leukemia"},{"issue":"6","key":"2026101310425877500_bib20","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1365-2141.2009.07697.x","article-title":"Mutations of polycomb-associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia","volume":"145","author":"Gelsi-Boyer","year":"2009","journal-title":"Br J Haematol"},{"issue":"5","key":"2026101310425877500_bib21","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/leu.2010.20","article-title":"Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"issue":"11","key":"2026101310425877500_bib22","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1038\/leu.2009.141","article-title":"Mutations of ASXL1 gene in myeloproliferative neoplasms","volume":"23","author":"Carbuccia","year":"2009","journal-title":"Leukemia"},{"issue":"6","key":"2026101310425877500_bib23","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1038\/leu.2010.65","article-title":"High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression","volume":"24","author":"Boultwood","year":"2010","journal-title":"Leukemia"},{"issue":"1","key":"2026101310425877500_bib24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1365-2141.2010.08196.x","article-title":"Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations","volume":"150","author":"Sugimoto","year":"2010","journal-title":"Br J Haematol"},{"issue":"21","key":"2026101310425877500_bib25","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1182\/blood-2010-06-292433","article-title":"CBL, CBLC, TET2, ASXL1, and IDH1\/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia","volume":"117","author":"Makishima","year":"2011","journal-title":"Blood"},{"issue":"1","key":"2026101310425877500_bib26","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/leu.2012.262","article-title":"ASXL1 exon 12 mutations are frequent in AML with intermediate risk karyotype and are independently associated with an adverse outcome","volume":"27","author":"Schnittger","year":"2013","journal-title":"Leukemia"},{"issue":"18","key":"2026101310425877500_bib27","first-page":"2214","article-title":"A practical approach to curate clonal hematopoiesis of indeterminate potential in human genetic data sets","volume":"141","author":"Vlasschaert","year":"2023","journal-title":"Blood"},{"issue":"7","key":"2026101310425877500_bib28","first-page":"364","article-title":"The PHD finger: a versatile epigenome reader","volume":"36","author":"Sanchez","year":"2011","journal-title":"Trends Biochem Sci"},{"issue":"2","key":"2026101310425877500_bib29","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.ccr.2012.06.032","article-title":"ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression","volume":"22","author":"Abdel-Wahab","year":"2012","journal-title":"Cancer Cell"},{"issue":"9","key":"2026101310425877500_bib30","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1186\/1476-4598-9-151","article-title":"Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK\/T-cell lines","volume":"17","author":"Nagel","year":"2010","journal-title":"Mol Cancer"},{"issue":"24","key":"2026101310425877500_bib31","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1101\/gad.225888.113","article-title":"Nucleosome-binding activities within JARID2 and EZH1 regulate the function of PRC2 on chromatin","volume":"27","author":"Son","year":"2013","journal-title":"Genes Dev"},{"key":"2026101310425877500_bib32","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.mcn.2013.07.012","article-title":"Ezh1 and Ezh2 differentially regulate PSD-95 gene transcription in developing hippocampal neurons","volume":"57","author":"Henriquez","year":"2013","journal-title":"Mol Cel Neurosci"},{"issue":"10","key":"2026101310425877500_bib33","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1182\/blood-2015-03-634428","article-title":"Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner","volume":"126","author":"Mochizuki-Kashio","year":"2015","journal-title":"Blood"},{"issue":"8","key":"2026101310425877500_bib37","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/s41375-021-01121-8","article-title":"Asxl1 C-terminal mutation perturbs neutrophil differentiation in zebrafish","volume":"35","author":"Fang","year":"2021","journal-title":"Leukemia"},{"key":"2026101310425877500_bib82","first-page":"e67463","article-title":"Optimized intravenous injection in adult zebrafish","volume":"214","author":"He","year":"2024","journal-title":"J Vis Exp"},{"issue":"5","key":"2026101310425877500_bib44","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nbt.4096","article-title":"Integrating single-cell transcriptomic data across different conditions, technologies, and species","volume":"36","author":"Butler","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2026101310425877500_bib45","doi-asserted-by":"crossref","first-page":"2796","DOI":"10.1038\/s41467-020-16515-y","article-title":"Single-cell transcriptomic analysis identifies the conversion of zebrafish Etv2-deficient vascular progenitors into skeletal muscle","volume":"11","author":"Chestnut","year":"2020","journal-title":"Nat Commun"},{"issue":"13","key":"2026101310425877500_bib46","doi-asserted-by":"crossref","first-page":"2687","DOI":"10.1182\/bloodadvances.2020002993","article-title":"Essential role for Gata2 in modulating lineage output from hematopoietic stem cells in zebrafish","volume":"5","author":"Gioacchino","year":"2021","journal-title":"Blood Adv"},{"key":"2026101310425877500_bib47","doi-asserted-by":"crossref","first-page":"e55792","DOI":"10.7554\/eLife.55792","article-title":"An improved zebrafish transcriptome annotation for sensitive and comprehensive detection of cell type-specific genes","volume":"9","author":"Lawson","year":"2020","journal-title":"Elife"},{"issue":"6","key":"2026101310425877500_bib48","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1084\/jem.20152013","article-title":"Single-cell transcriptional analysis of normal, aberrant, and malignant hematopoiesis in zebrafish","volume":"213","author":"Moore","year":"2016","journal-title":"J Exp Med"},{"issue":"7622","key":"2026101310425877500_bib49","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/nature19348","article-title":"Single-cell analysis of mixed-lineage states leading to a binary cell fate choice","volume":"537","author":"Olsson","year":"2016","journal-title":"Nature"},{"issue":"14","key":"2026101310425877500_bib50","doi-asserted-by":"crossref","first-page":"e2015748118","DOI":"10.1073\/pnas.2015748118","article-title":"A single-cell resolution developmental atlas of hematopoietic stem and progenitor cell expansion in zebrafish","volume":"118","author":"Xia","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2026101310425877500_bib51","doi-asserted-by":"crossref","first-page":"3660","DOI":"10.1038\/s41467-018-06094-4","article-title":"CXCL12 and MYC control energy metabolism to support adaptive responses after kidney injury","volume":"9","author":"Yakulov","year":"2018","journal-title":"Nat Commun"},{"issue":"10","key":"2026101310425877500_bib52","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/nmeth.4402","article-title":"Reversed graph embedding resolves complex single-cell trajectories","volume":"14","author":"Qiu","year":"2017","journal-title":"Nat Methods"},{"issue":"4","key":"2026101310425877500_bib53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nbt.2859","article-title":"The dynamics and regulators of cell fate decisions are revealed by pseudotemporal ordering of single cells","volume":"32","author":"Trapnell","year":"2014","journal-title":"Nat Biotechnol"},{"issue":"11","key":"2026101310425877500_bib54","doi-asserted-by":"crossref","first-page":"2789","DOI":"10.1007\/s11517-020-02249-y","article-title":"GFNB: Gini index-based Fuzzy Naive Bayes and blast cell segmentation for leukemia detection using multi-cell blood smear images","volume":"58","author":"Das","year":"2020","journal-title":"Med Biol Eng Comput"},{"issue":"52","key":"2026101310425877500_bib55","doi-asserted-by":"crossref","first-page":"15084","DOI":"10.1073\/pnas.1617929114","article-title":"The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development","volume":"113","author":"Lemonnier","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8","key":"2026101310425877500_bib56","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/nmeth.3031","article-title":"Optimized cell transplantation using adult rag2 mutant zebrafish","volume":"11","author":"Tang","year":"2014","journal-title":"Nat Methods"},{"issue":"1","key":"2026101310425877500_bib57","doi-asserted-by":"crossref","first-page":"6061","DOI":"10.1038\/s41467-021-26093-2","article-title":"TET2 mutations are associated with hypermethylation at key regulatory enhancers in normal and malignant hematopoiesis","volume":"12","author":"Tulstrup","year":"2021","journal-title":"Nat Commun"},{"issue":"2","key":"2026101310425877500_bib58","doi-asserted-by":"crossref","first-page":"201","DOI":"10.4161\/epi.7.2.19015","article-title":"Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia","volume":"7","author":"Yamazaki","year":"2012","journal-title":"Epigenetics"},{"issue":"11","key":"2026101310425877500_bib59","doi-asserted-by":"crossref","first-page":"eaau6986","DOI":"10.1126\/sciadv.aau6986","article-title":"TET2 coactivates gene expression through demethylation of enhancers","volume":"4","author":"Wang","year":"2018","journal-title":"Sci Adv"},{"issue":"12","key":"2026101310425877500_bib60","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1038\/s41589-023-01457-5","article-title":"Targeting ROS production through inhibition of NADPH oxidases","volume":"19","author":"Reis","year":"2023","journal-title":"Nat Chem Biol"},{"issue":"19","key":"2026101310425877500_bib61","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2013-04-491944","article-title":"Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling","volume":"122","author":"Hole","year":"2013","journal-title":"Blood"},{"issue":"8","key":"2026101310425877500_bib62","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","article-title":"Integrative analysis of drug response and clinical outcome in acute myeloid leukemia","volume":"40","author":"Bottomly","year":"2022","journal-title":"Cancer Cell"},{"issue":"1","key":"2026101310425877500_bib63","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12185-015-1769-1","article-title":"Pseudo-Pelger-Hu\u00ebt anomaly and granulocytic dysplasia associated with human granulocytic anaplasmosis","volume":"102","author":"Lee","year":"2015","journal-title":"Int J Hematol"},{"issue":"3","key":"2026101310425877500_bib64","doi-asserted-by":"crossref","first-page":"474","DOI":"10.3324\/haematol.2013.097394","article-title":"Hemophagocytic syndrome in patients with acute myeloid leukemia undergoing intensive chemotherapy","volume":"99","author":"Delavigne","year":"2014","journal-title":"Haematologica"},{"issue":"4","key":"2026101310425877500_bib65","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood.V57.4.798.798","article-title":"The significance of splenomegaly in 101 adults with acute lymphoblastic leukemia (ALL) at presentation and during remission","volume":"57","author":"Friedman","year":"1981","journal-title":"Blood"},{"issue":"12","key":"2026101310425877500_bib66","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1084\/jem.20131141","article-title":"Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo","volume":"210","author":"Abdel-Wahab","year":"2013","journal-title":"J Exp Med"},{"issue":"4","key":"2026101310425877500_bib67","doi-asserted-by":"crossref","first-page":"e2208176120","DOI":"10.1073\/pnas.2208176120","article-title":"Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells","volume":"120","author":"Fortin","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"2026101310425877500_bib68","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1038\/s41375-025-02790-5","article-title":"asxl1 C-terminal truncation and SRSF2 mutation drive leukemogenesis via immune reprogramming","volume":"39","author":"Tu","year":"2025","journal-title":"Leukemia"},{"issue":"8","key":"2026101310425877500_bib69","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1056\/NEJMoa0808710","article-title":"IDH1 and IDH2 mutations in gliomas","volume":"360","author":"Yan","year":"2009","journal-title":"N Engl J Med"},{"issue":"9","key":"2026101310425877500_bib70","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41408-021-00541-0","article-title":"ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine","volume":"11","author":"Rahmani","year":"2021","journal-title":"Blood Cancer J"},{"issue":"7","key":"2026101310425877500_bib71","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1182\/blood.2021012519","article-title":"Asxl1 loss cooperates with oncogenic Nras in mice to reprogram the immune microenvironment and drive leukemic transformation","volume":"139","author":"You","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026101310425877500_bib72","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1161\/ATVBAHA.108.163592","article-title":"AP-1-dependent transcriptional regulation of NADPH oxidase in human aortic smooth muscle cells: role of p22phox subunit","volume":"28","author":"Manea","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2026101310425877500_bib73","doi-asserted-by":"crossref","first-page":"312","DOI":"10.3390\/antiox13030312","article-title":"Reactive oxygen species signaling and oxidative stress: transcriptional regulation and evolution","volume":"13","author":"Hong","year":"2024","journal-title":"Antioxidants (Basel)"},{"issue":"7","key":"2026101310425877500_bib74","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1182\/blood.2021012778","article-title":"PLCG1 is required for AML1-ETO leukemia stem cell self-renewal","volume":"139","author":"Schnoeder","year":"2022","journal-title":"Blood"},{"issue":"5","key":"2026101310425877500_bib75","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.amjms.2017.01.019","article-title":"AP-1 expression and its clinical relevance in immune disorders and cancer","volume":"353","author":"Trop-Steinberg","year":"2017","journal-title":"Am J Med Sci"},{"issue":"1","key":"2026101310425877500_bib76","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s12672-025-01783-1","article-title":"Advances in the relationship between AP-1 and tumorigenesis, development and therapy resistance","volume":"16","author":"Xue","year":"2025","journal-title":"Discov Oncol"},{"issue":"5","key":"2026101310425877500_bib77","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/j.celrep.2015.06.069","article-title":"Chronic FLT3-ITD signaling in acute myeloid leukemia is connected to a specific chromatin signature","volume":"12","author":"Cauchy","year":"2015","journal-title":"Cell Rep"},{"issue":"4","key":"2026101310425877500_bib78","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.ccell.2018.08.015","article-title":"The oncogenic transcription factor RUNX1\/ETO corrupts cell cycle regulation to drive leukemic transformation","volume":"34","author":"Martinez-Soria","year":"2018","journal-title":"Cancer Cell"},{"issue":"4","key":"2026101310425877500_bib79","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/nm1388","article-title":"Reactive oxygen species act through p38 MAPK to limit the lifespan of hematopoietic stem cells","volume":"12","author":"Ito","year":"2006","journal-title":"Nat Med"},{"key":"2026101310425877500_bib80","doi-asserted-by":"crossref","first-page":"889875","DOI":"10.3389\/fimmu.2022.889875","article-title":"Reactive oxygen species and metabolism in leukemia: a dangerous liaison","volume":"13","author":"Romo-Gonzalez","year":"2022","journal-title":"Front Immunol"},{"issue":"1","key":"2026101310425877500_bib81","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","author":"Venugopal","year":"2022","journal-title":"Blood Cancer J"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6610\/2591941\/blooda_adv-2026-019586-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6610\/2591941\/blooda_adv-2026-019586-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:12Z","timestamp":1791902592000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6610\/569825\/Comutation-of-asxl1-and-IDH2R172K-enhances"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":73,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026019586","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,28]]}}}